1604610

Risedronate sodium

United States Pharmacopeia (USP) Reference Standard

• 同義詞: Risedronic acid monosodium salt hemi(pentahydrate)
• 經驗公式（希爾表示法）: C₇H₁₀NNaO₇P₂ · 2.5H₂O
• CAS號碼: 329003-65-8
• 分子量：: 350.13
• MDL號碼: MFCD01706268
• 分類程式碼代碼: 41116107
• NACRES: NA.24

屬性

• 等級: pharmaceutical primary standard
• API 家族: risedronate
• 製造商／商標名: USP
• 應用: pharmaceutical (small molecule)
• 形式: neat
• SMILES 字串: OP(C(P(O)([O-])=O)(O)CC1=CC=CN=C1)(O)=O.[Na+]
• InChI: 1S/2C7H11NO7P2.2Na.5H2O/c2*9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;;;;;;;/h2*1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);;;5*1H2/q;;2*+1;;;;;/p-2
• InChI 密鑰: HYFDYHPNTXOPPO-UHFFFAOYSA-L

描述

一般說明

Risedronate sodium is a member of the pyridinyl class of bisphosphonates. It is mostly used as an antiresorptive agent. It can be used in treating and preventing postmenopausal and glucocorticoid-induced osteoporosis.

應用

Risedronate sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

• Risedronate Sodium Tablets
• Risedronate Sodium Delayed-Release Tablets

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

安全資訊

• 象形圖: GHS08,GHS07
• 訊號詞: Warning
• 危險聲明: H302,H319,H361,H371
• 防範說明: P202 - P260 - P264 - P301 + P312 - P305 + P351 + P338 - P308 + P311
• 危險分類: Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - STOT SE 2
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable